CDXS vs TECH vs A Stock Comparison

Codexis, Bio-Techne and Agilent Technologies Prices as of Oct 27, 2026 Peers: Industry group
1 more company in this comparison (QGEN) Create a free account to keep reading and compare up to 10 companies.
CDXS Codexis, Inc.
$1.28 -3.0% 1M -50.8% 1Y
Market cap
$116.98M
P/E
–
Revenue (TTM)
$77.68M
Div. yield
–
Life Sciences Tools Healthcare
1 win
TECH BIO-TECHNE Corp
$72.60 0.0% 1M +13.0% 1Y
Market cap
$11.33B
P/E
62.3x
Revenue (TTM)
$1.22B
Div. yield
0.44%
Life Sciences Tools Healthcare
2 wins
A Agilent Technologies, Inc.
$177.48 +2.7% 1M +21.1% 1Y
Market cap
$50.04B
P/E
34.8x
Revenue (TTM)
$7.37B
Div. yield
0.58%
Life Sciences Tools Healthcare
9 wins

Head to Head

12 decided of 12

Agilent Technologies leads on 9 of the 12 questions below (Agilent Technologies 9, Bio-Techne 2, Codexis 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCDXSTECHALeader
Larger companyMarket capitalisation $116.98M $11.33B $50.04B A
Cheaper on earningsLower P/E, profitable companies only -3.8x 62.3x 34.8x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 33.6x 27.1x A
Faster revenue growthRevenue growth, trailing twelve months +35.9% -0.4% +8.6% CDXS
More profitableNet margin, trailing twelve months -39.6% 15.0% 19.5% A
Better return on capitalReturn on invested capital -35.1% 8.3% 13.1% A
Less leveragedLower net debt / EBITDA 0.7x -0.2x 1.1x TECH
Higher dividend yieldTrailing dividend yield — 0.44% 0.58% A
Better 1-year returnPrice return, last 12 months -50.8% +13.0% +21.1% A
Better 5-year returnAnnualised price return, 5 years -48.4%/yr -10.8%/yr +2.6%/yr A
Less volatileAnnualised volatility, 1 year 86.7% 43.5% 32.4% A
Higher overall scoreMean of the five percentile scores vs peers 45/100 66/100 62/100 TECH

Percentile Scorecard

CDXSTECHA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCDXSTECHA
Valuation 40 #137 of 227 58 #96 of 227 58 #97 of 227
Growth 67 #73 of 219 40 #131 of 219 38 #137 of 219
Profitability 43 #117 of 206 94 #14 of 206 91 #20 of 206
Financial Health 30 #166 of 238 86 #34 of 238 55 #107 of 238
Shareholder Returns 42 #78 of 134 51 #66 of 134 71 #40 of 134
Overall 45 66 62
  • CDXS ranked among 247 companies in Medical Devices and Diagnostics
  • TECH ranked among 247 companies in Medical Devices and Diagnostics
  • A ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCDXSTECHASPY
1 month -3.0%0.0%+2.7% -0.2%
3 months -14.7%+0.7%+26.3% +3.9%
6 months -54.6%+35.7%+54.5% +8.2%
Year to date -21.5%+23.4%+30.4% +12.9%
1 year -50.8%+13.0%+21.1% +12.3%
3 years -17.4%+21.9%+72.7% +87.4%
3 years, per year -6.2%+6.8%+20.0% +23.3%
5 years -96.3%-43.6%+13.9% +67.9%
5 years, per year -48.4%-10.8%+2.6% +10.9%
10 years -71.6%+187.0%+309.1% +261.1%
10 years, per year -11.8%+11.1%+15.1% +13.7%

Risk

MeasureCDXSTECHASPY
Volatility, 1Y 86.7%43.5%32.4% 12.7%
Downside volatility, 1Y 91.1%43.4%27.5% 12.7%
Beta vs S&P 500, 1Y 1.850.770.88 1.00
Return / volatility, 1Y -0.590.300.65 0.97
Max drawdown, 5Y -97.7%-67.0%-39.6% -25.4%
From 52-week high -55.1%-0.1%-0.1% -1.2%
52-week high $2.85$72.69$177.72 $779.14
52-week low $0.98$43.30$110.24 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCDXSTECHA
P/E now vs peer median -3.8xmedian 29.6x 62.3xmedian 29.6x 34.8xmedian 29.6x
P/S now vs peer median 1.5xmedian 2.9x 9.3xmedian 2.9x 6.8xmedian 2.9x
EV/EBITDA now vs peer median -4.9xmedian 17.4x 32.3xmedian 17.4x 27.3xmedian 17.4x
P/FCF now vs peer median -9.6xmedian 22.3x 43.1xmedian 22.3x 39.5xmedian 22.3x
P/B now vs peer median 3.5xmedian 2.3x 5.4xmedian 2.3x 6.8xmedian 2.3x
PEG now vs peer median -0.14median 1.04 -4.77median 1.04 3.54median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCDXSTECHA
Revenue $77.68M $1.22B $7.37B
Gross profit $67.60M $799.07M $3.97B
Operating income -$27.66M $251.89M $1.64B
Net income -$30.72M $181.86M $1.44B
Free cash flow -$12.18M $263.22M $1.27B
R&D $48.74M $94.77M $485.00M
EPS (diluted) $-0.34 $1.16 $5.09
Cash & equivalents $27.17M $264.71M $1.76B
Total debt $40.88M $200.00M $3.95B
Shares (diluted) 91.05M 157.01M 283.00M
Enterprise value -$140.07M $10.54B $42.93B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCDXSTECHA
P/E -3.8x 62.3x 34.8x
P/FCF -9.6x 43.1x 39.5x
P/Operating cash flow -11.2x 38.8x 31.1x
P/S 1.5x 9.3x 6.8x
P/B 3.5x 5.4x 6.8x
P/Tangible book 3.5x 6.3x 7.8x
EV/EBITDA -4.9x 32.3x 27.3x
EV/EBIT -3.7x 44.7x 31.9x
EV/Revenue 1.3x 9.3x 7.1x
EV/FCF -8.5x 42.8x 41.2x
EV/Operating cash flow -9.9x 38.6x 32.5x
PEG (3Y EPS CAGR) -0.14 -4.77 3.54

Growth

14 metrics
MetricCDXSTECHA
Revenue growth (1Y) 35.9% -0.4% 8.6%
Revenue CAGR (3Y) -7.8% 2.2% 1.8%
Gross profit growth (1Y) 52.4% 1.1% 11.2%
Gross profit CAGR (3Y) -2.6% 1.3% 3.7%
Operating income growth (1Y) 51.7% 146.3% 13.5%
Operating income CAGR (3Y) 22.8% -5.5% 5.1%
Net income growth (1Y) 52.7% 147.8% 18.0%
Net income CAGR (3Y) 18.5% -14.0% 8.3%
EPS growth (1Y) 55.7% 152.0% 18.9%
EPS CAGR (3Y) 26.2% -13.1% 9.8%
Operating cash flow growth (1Y) 83.0% 1.6% 7.6%
Operating cash flow CAGR (3Y) -152.3% 4.7% -1.9%
Free cash flow growth (1Y) 82.0% 2.6% 16.5%
Free cash flow CAGR (3Y) -26.3% 6.8% -3.7%

Profitability

14 metrics
MetricCDXSTECHA
Gross margin 87.0% 65.8% 53.8%
EBITDA margin -27.0% 28.7% 25.9%
Operating margin -35.6% 20.7% 22.2%
Pretax margin -39.5% 19.8% 22.5%
Net margin -39.6% 15.0% 19.5%
FCF margin -15.7% 21.7% 17.2%
Operating cash flow margin -13.4% 24.0% 21.8%
Return on equity -80.6% 8.7% 19.9%
Return on assets -24.6% 7.1% 10.7%
Return on invested capital -35.1% 8.3% 13.1%
Return on capital employed -27.3% 10.5% 14.6%
Asset turnover 0.6x 0.5x 0.5x
Cash conversion (OCF / net income) 0.3x 1.6x 1.1x
Stock comp / revenue 9.9% 0.5% 1.8%

Financial Health

11 metrics
MetricCDXSTECHA
Debt / assets 34.0% 7.7% 28.3%
Debt / equity 1.2x 0.1x 0.5x
Net debt / EBITDA 0.7x -0.2x 1.1x
Debt / FCF -3.4x 0.8x 3.1x
Liabilities / assets 72.5% 18.5% 47.3%
Equity / assets 27.5% 81.5% 52.7%
Interest coverage – 26.2x 15.5x
Current ratio 3.1x 4.5x 2.1x
Quick ratio 2.9x 2.9x 1.4x
Cash ratio 2.3x 1.6x 0.8x
Altman Z-score -6.14 15.89 5.86

Shareholder Returns

7 metrics
MetricCDXSTECHA
Dividend yield – 0.4% 0.6%
Net buyback yield -0.3% -0.3% 0.6%
Shareholder yield -0.3% 0.1% 1.2%
Payout ratio (earnings) – 27.4% 19.9%
Payout ratio (FCF) – 19.0% 22.6%
Dividend growth (1Y) – -0.9% 2.1%
Dividend CAGR (3Y) – -0.2% 3.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCDXSTECHA
Forward P/E – 33.6xFY2027 27.1xFY2026
EPS, next fiscal year $-0.37FY2026 $2.16FY2027 $6.54FY2026
EPS growth, next FY – +11.9%FY2027 +17.0%FY2026
EPS growth, the year after – +5.1% +0.3%
Revenue, next fiscal year $77.93MFY2026 $1.19BFY2027 $7.87BFY2026
Revenue growth, next FY +10.7%FY2026 -2.1%FY2027 +15.3%FY2026
Revenue growth, the year after +9.2% +13.5% -5.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCDXSTECHA
Held by institutions 71.0% 100.0% 92.6%
Institutions holding 148 597 1,123
Change in shares held, QoQ -2.4% -0.6% +3.2%
Institutions buying 88 293 600
Institutions selling 36 241 350
Buyers to sellers 2.44 1.22 1.71

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CDXSTECHA
CDXS 1.00 0.14 0.12
TECH 0.14 1.00 0.48
A 0.12 0.48 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CDXS, TECH and A?

Agilent Technologies (A) is the largest by market capitalisation: Codexis (CDXS) $116.98M, Bio-Techne (TECH) $11.33B, Agilent Technologies (A) $50.04B.

Which stock is cheaper, CDXS, TECH and A?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Codexis (CDXS) -3.8x, Bio-Techne (TECH) 62.3x, Agilent Technologies (A) 34.8x). On next year's consensus earnings, Agilent Technologies (A) is cheapest (Bio-Techne (TECH) 33.6x, Agilent Technologies (A) 27.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Codexis (CDXS) grew revenue fastest over the trailing twelve months: Codexis (CDXS) +35.9%, Bio-Techne (TECH) -0.4%, Agilent Technologies (A) +8.6%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Codexis (CDXS) -39.6%, Bio-Techne (TECH) 15.0%, Agilent Technologies (A) 19.5%). On return on invested capital, Agilent Technologies (A) leads (Codexis (CDXS) -35.1%, Bio-Techne (TECH) 8.3%, Agilent Technologies (A) 13.1%).

Which stock has performed better?

Over the past year Agilent Technologies (A) returned the most: Codexis (CDXS) -50.8%, Bio-Techne (TECH) +13.0%, Agilent Technologies (A) +21.1%. Over five years, Agilent Technologies (A) compounded fastest (Codexis (CDXS) -48.4%/yr, Bio-Techne (TECH) -10.8%/yr, Agilent Technologies (A) +2.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Agilent Technologies (A) has the highest dividend yield: Bio-Techne (TECH) 0.44%, Agilent Technologies (A) 0.58%. Codexis (CDXS) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Agilent Technologies (A) has been the steadiest (Codexis (CDXS) 86.7%, Bio-Techne (TECH) 43.5%, Agilent Technologies (A) 32.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CDXS, TECH and A?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 9. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.